Table 3. Multivariate model of factors associated with the occurrence of MACE during follow up.
| HR* (CI 95%*) | P value** | |
|---|---|---|
| CAD: Time since first mention in EHRs | 0.77 (0.72, 0.84) | < 0.001** |
| TIA | 1.51 (0.96, 2.38) | 0.073 |
| Heart failure | 1.23 (1.00, 1.52) | 0.053 |
| Heart valve disease | 1.22 (1.02, 1.46) | 0.031** |
| Multivessel coronary disease | 1.27 (1.07, 1.51) | 0.005** |
| Diabetic retinopathy | 1.28 (0.95, 1.73) | 0.102 |
| Diabetic neuropathy | 0.63 (0.37, 1.10) | 0.107 |
| CKD | 0.82 (0.64, 1.05) | 0.114 |
| COPD/Asthma | 1.28 (1.04, 1.59) | 0.021** |
| Treatments | ||
| Sulfonylureas | 1.18 (0.98, 1.44) | 0.086 |
| Alpha-glucosidase | 0.30 (0.07, 1.19) | 0.087 |
| Insulin | 1.53 (1.26, 1.85) | < 0.001** |
| Vitamin-k antagonist oral anticoagulant | 0.77 (0.59, 1.02) | 0.073 |
| Clopidogrel | 0.83 (0.70, 0.99) | 0.039** |
| Ranolazines | 1.30 (0.99, 1.70) | 0.058 |
| Statins | 0.62 (0.48, 0.81) | < 0.001** |
**Statistical differences between MACE and No-MACE patients were considered when p < 0.05 in two-tailed tests. HR = Hazards ratio; CI = Confidence Interval; CAD = Coronary artery disease; TIA = Transient ischemic attack; CKD = Chronic kidney disease; COPD = Chronic obstructive pulmonary disease.